Evidence map›Paper›PMID 34001867›Full record

Trial reportBlood cancer journal2021

Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma.

Ulrich Dührsen, Mareike Tometten, Frank Kroschinsky, Arnold Ganser, Stefan Ibach, Stefanie Bertram, Andreas Hüttmann

Abstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ulrich DührsenKlinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany. ulrich.duehrsen@uk-essen.de.ORCID 0000-0002-4034-9472
Mareike TomettenKlinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Medizinische Fakultät, RWTH Aachen Universität, Aachen, Germany.
Frank KroschinskyMedizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Arnold GanserKlinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany.
Stefan IbachX-act Cologne Clinical Research GmbH, Köln, Germany.
Stefanie BertramInstitut für Pathologie, Universitätsklinikum Essen, Essen, Germany.
Andreas HüttmannKlinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany.ORCID 0000-0003-2230-3873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCytarabineFemaleHumansLenalidomideLeucovorinLymphoma, Large B-Cell, DiffuseMaleMethotrexateMiddle AgedNeoplasm Recurrence, LocalRituximabSurvival AnalysisCytarabineLenalidomideLeucovorinMethotrexateRituximab

Identifiers

PMID34001867
PMCPMC8129096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.